VP, Metabolic Disease

The Opportunity
The heart of insitro’s strategy is the application of cutting edge machine learning to human biological data in order to discover medicines that matter to patients. We believe insitro’s capabilities position us to significantly address the burden imposed by metabolic diseases, and so we are seeking a leader to drive our research in this field. In this leadership role, you will build the metabolic diseases therapeutic area (TA), formulate the research strategy for this TA, and operate as a key member of insitro’s R&D team.

Your primary duties will be to:
- set the direction for insitro’s therapeutic strategy in metabolic disease indications, with an initial emphasis on liver disease; 
- work with other company leaders to identify and prioritize target indications and biologic mechanisms in this TA, and participate in prioritizing indications and biologies in other TAs;
- partner with our corporate development team to identify, acquire or construct relevant human cohort data sets that can help inform our understanding of the disease;
- work cross-functionally to design both experimental assays and machine learning models that will help deconvolute these therapeutic mechanisms, stratify patients and identify drug targets; 
- lead efforts to follow up on these targets with the goal of producing viable therapeutic interventions;
- lead external collaborations with partners and with other organizations and individuals in efforts related to the metabolic diseases area.
 
You will be joining a biotech startup that has long-term stability due to significant funding, but whose drug discovery and development organization is very much in formation. A lot can change in this early and exciting phase, providing many opportunities for significant impact. You will work closely with a very talented team, learn a broad range of skills, and help shape insitro’s culture, strategic direction, and outcomes. Join us, and help make a difference to patients!
 

About You
- PhD or MD/PhD in technical field (Cardiometabolic, Genetics, etc.) or equivalent practical experience
- 15+ years of post-training experience in a role involving translational science or drug research and development, with at least 10 years of relevant industry experience that spans both research and early clinical development
- A track record of using unbiased, data-driven approaches for scientific and/or drug discovery 
- A strong scientific track record in metabolic diseases
- An openness to using human-relevant, cell-based systems as models of metabolic diseases
- A record of innovation, exemplified by generating ideas, launching projects and advancing candidates into the clinic
- Extensive experience with a broad spectrum of state-of-the-art cellular and biochemical assays, including a track record of novel method development
- Strong background in human genetics
- Demonstrated track record in building partnerships or collaborations with data scientists or computational biologists
- Track record of building and leading a high-performance team, including goal setting
- Ability to operate within a fast-moving, startup environment
- Highly collaborative, team-oriented, and an effective communicator
- Passion for making a difference in the world


Benefits at insitro
- Excellent medical, dental, and vision coverage; insitro pays 100% of premiums for employees
- Excellent mental health and well-being support
- Open vacation policy
- Access to free onsite baristas and cafe with daily lunch and breakfast
- Access to free onsite fitness center
- Commuter benefits
- Paid parental leave
- Competitive pay and 401(k) matching
- Flexible work schedule (on site and remote)


About insitro
insitro is a data-driven drug discovery and development company using machine learning and data at scale to transform the way that drugs are discovered and developed for patients. insitro is developing predictive machine learning models to discover underlying biologic state based on human cohort data and in-house generated cellular data at scale. These predictive models can be brought to bear on key bottlenecks in pharmaceutical R&D to advance novel targets and patient biomarkers, design therapeutics, and inform clinical strategy. insitro is advancing a wholly owned and partnered pipeline of biologic insights and molecules in neuroscience and metabolic diseases. Since formation in mid 2018, insitro has raised over $700 million from top tech, biotech, and crossover investors and from collaborations with pharmaceutical partners. For more information on insitro, please visit the company’s website at www.insitro.com.